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Results
139
EDB-FN expression is significantly elevated in breast cancer
As a critical ECM component, FN1 is overexpressed in multiple cancer types (Bae et al., 141 2013 , Suer et al., 1996 , Saito et al., 2008 , Menendez et al., 2005 . Here, the expression of the FN1 142 transcript containing the EDB-FN exon (ENST00000323926) was assayed by performing 143 differential gene expression analysis on RNA-Seq patient data from TCGA database. As shown in 
Growth and morphology changes in 2D-and 3D-cultured breast cancer cells with TGF-β
154 treatment and drug resistance 155 To assess the changes in EDB-FN expression levels when breast cancer cells gain 156 significant survival advantages, the two cell lines with the lowest EDB-FN expression and 157 epithelial phenotype, namely MCF7 and MDA-MB-468 cells, were chosen. Two selective 158 pressures were applied: 1) long-term treatment with TGF-β (5 ng/mL) to induce EMT (Xu et al., 159 2009) to generate MCF7-TGFβ and MDA-MB-468-TGFβ cells and 2) acquired chemoresistance 160 to Palbociclib, a cyclin-dependent kinase (CDK) inhibitor (Chen et al., 2018) , and to Paclitaxel, 161 an anti-microtubule agent (Barbuti and Chen, 2015) , to generate MCF7-DR and MDA-MB-468-162 DR cells, respectively. The parent and derivative cell lines were characterized for their 163 morphology, and molecular and functional phenotypes. culture. Long-term treatment with TGF-β and development of resistance to Palbociclib resulted in 166 morphological changes to a more mesenchymal phenotype, which was more pronounced in the 167 MCF7-DR cells than in MCF7-TGFβ cells. On the other hand, the MDA-MB-468 cells did not 168 exhibit overt changes in morphology with TGF-β treatment and development of resistance to 169 Paclitaxel. However, the MDA-MB-468-TGFβ showed increased growth rate compared to the 170 parent MDA-MB-468 cells.
171
In addition to 2D culture, the cells were grown in Matrigel to facilitate the establishment 172 of a conducive ECM. As shown in Fig. 2B , in 3D culture, the low-risk HR + MCF7 cells showed 173 negligible tumor spheroid formation while the more invasive MDA-MB-468 cells showed 174 proliferative network formation. The MCF7-TGFβ and MCF7-DR cells formed tumor spheroids, 175 unlike the parent MCF7 cells, while the MDA-MB-468-TGFβ and MDA-MB-468-DR cells 176 formed similar proliferative networks as their parent counterparts. These results highlight the 177 different properties of each cancer cell type and its distinct response to external mitogenic stimuli. 179 Next, we analyzed the molecular and functional changes in the TGF-β-treated and drug-180 resistant breast cancer cells. TGF-β is a potent inducer of EMT, a critical step towards initiation 181 of metastasis (Fedele et al., 2017) . Similarly, the signaling programs of EMT and drug resistance 182 are intricately related, where EMT-like molecular signature can antagonize chemotherapy in breast 183 cancer (Huang et al., 2015) . Consequently, the mRNA and protein expression of the common EMT 468-DR cells (Fig. 3C) . 191 At the protein level, both MCF-TGFβ and MCF7-DR cells showed upregulated N-cad and 192 Slug expression while the E-cad expression did not significantly decrease ( Fig. 3D) , indicating 193 that the MCF7 cells gain a partial EMT-like phenotype with TGF-β treatment and development of Slug expression, compared to the parent cells ( Fig. 3E) . These results indicate that while both the MDA-MB-468-TGFβ and MDA-MB-468-DR cells overexpress the migratory protein Slug, the 198 former did not undergo EMT with TGF-β treatment while the latter possibly gained a hybrid E-M 199 phenotype with drug resistance.
178
Increased migration in breast cancer cells with TGF-β treatment and drug resistance
200
The treated cell populations were analyzed for their ability to invade through a layer of 201 matrigel coated in transwell inserts. As shown in Fig. 3F , both the TGF-β treatment and drug 202 resistance conferred significant invasive advantage on the MCF7 and MDA-MB-468 cells, 203 rendering them more motile than their parent counterparts, as seen by the increased number of 204 crystal violet-stained migrated cells. Indeed, recent studies have revealed that the partial or hybrid 205 E-M phenotype is attributed to the tumor cell plasticity and is extremely favorable for metastatic 206 dissemination (Kroger et al., 2019 , Saitoh, 2018 .
207
Increased EDB-FN expression in breast cancer cells with TGF-β treatment and drug resistance 208
The potential role of EDB-FN as a molecular marker for breast cancer aggressiveness was MK2206-HCl treatment (Fig. 5K) , suggesting that EDB-FN upregulation in these invasive cells 259 could be controlled, at least in part, through the phosphoAKT-SRp55 signaling pathway. 
Therapeutic ablation of AKT in invasive breast cancer cells decreases invasion and EDB-FN
310
EDB-FN is overexpressed in multiple types of cancer, including breast, colorectal, oral, 311 bladder, lung, and prostate (Bae et al., 2013 , Lyons et al., 2001 , Inufusa et al., 1995 , Arnold et al., 312 2016 , Khan et al., 2005 , Albrecht et al., 1999 . Originally thought to be secreted only by cancer-313 associated fibroblasts (CAFs) and endothelial cells, EDB-FN is now known to be abundantly 314 produced by tumor cells, especially invasive tumor cells (Han and Lu, 2017) . EDB-FN is 315 upregulated during embryogenesis, temporally activated during wound healing, tissue repair, and 316 angiogenesis, but mostly absent from healthy adult tissues (White et al., 2008) . Additionally, by 317 virtue of its extracellular location and ready accessibility, EDB-FN has emerged as an attractive 318 target for designing new diagnostic and therapeutic regimens. Previous studies have already 319 demonstrated the potential of antibody-mediated EDB-FN targeting (using L19, BC-1) for 320 angiogenesis, inflammation, and cancer stem cell therapy (Mariani et al., 1997 , Tijink et al., 2009 .
321
EDB-FN-specific peptides, such as ZD2 and APTEDB, are advantageous for oncogenic ECM 322 targeting, by virtue of their small size, low immunogenicity, and high tissue penetration ability 323 (Han et al., 2015 , Sun et al., 2014 , Zahnd et al., 2010 . The specificity and superior binding of the 324 ZD2 probe for EDB-FN has direct translational implications. We have successfully demonstrated In summary, this research demonstrates that EDB-FN expression is strongly associated 332 with highly invasive breast cancer and with low-risk cells that evolve into high-risk cancer. 
